Clinical Trial Update: Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports results for nivolumab plus ipilimumab in limited-stage small cell lung cancer (NCT02046733), with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-08